Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.5K
Clinical Trials01:16

Clinical Trials

10.1K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
10.1K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

SBRT plus abiraterone acetate and ADT versus abiraterone acetate and ADT in oligometastatic castrate-resistant prostate cancer (ARTO): long-term, unplanned overall survival analysis of an open-label, randomised, phase 2 trial.

The Lancet. Oncology·2026
Same author

Renal Medullary Carcinoma: Utility of [<sup>18</sup>F]FDG PET/CT in Evaluating Extent of Disease and Impact on Treatment Management.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same author

Implementing intervention mapping to tailor the evidence-based PREDIMED intervention for medically underserved prostate cancer patients.

Translational behavioral medicine·2026
Same author

Survival Outcomes of a Smoking Cessation Treatment Program After Diagnosis of Bladder Cancer.

European urology oncology·2026
Same author

Feasibility of longitudinal relaxation rate mapping with non-Cartesian sampling and compressed sensing on a 1.5 T magnetic resonance linear accelerator.

Physics and imaging in radiation oncology·2026
Same author

Impact of intraoperative intravenous heparin bolus on clinical outcomes during radical nephrectomy and IVC tumor thrombectomy in renal cell carcinoma with level I-IV IVC thrombus: A multi-institutional study.

Urologic oncology·2026
Same journal

An Unprecedented Era of Innovation in Non-Muscle-Invasive Bladder Cancer.

The Urologic clinics of North America·2026
Same journal

Hubert Humphrey's Bladder Cancer: If He Could Have Time Traveled, Would that Have Changed the Outcome?

The Urologic clinics of North America·2026
Same journal

Key Clinical Trials Shaping the Future of Superficial High-Risk Bladder Cancer Management.

The Urologic clinics of North America·2026
Same journal

Future Directions: Artificial Intelligence and Digital Tools in Bladder Cancer Care.

The Urologic clinics of North America·2026
Same journal

Economic Considerations in the Management of Superficial Bladder Cancer.

The Urologic clinics of North America·2026
Same journal

Patient-Centered Approaches to Non-Muscle-Invasive Bladder Cancer Care.

The Urologic clinics of North America·2026
See all related articles

Related Experiment Video

Updated: Jan 10, 2026

A New Technique for Treating Low-risk Prostate Cancer&#8212;Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

647

Current and Upcoming Trials in Localized Prostate Cancer.

Landan P MacDonald1, Andrew M Fang1, Chad Tang2

  • 1Department of Urology, Unit 1373, 1515 Holcombe Boulevard, Houston, TX 77030, USA.

The Urologic Clinics of North America
|November 20, 2025
PubMed
Summary
This summary is machine-generated.

This review summarizes recent advances in localized prostate cancer (PCa) diagnosis and management. It highlights new treatments and ongoing trials to improve patient outcomes and reduce side effects.

Keywords:
Clinical trialsGenomic classifiersImagingLocalized prostate cancerRadiotherapy

More Related Videos

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

17.0K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.7K

Related Experiment Videos

Last Updated: Jan 10, 2026

A New Technique for Treating Low-risk Prostate Cancer&#8212;Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

647
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

17.0K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.7K

Area of Science:

  • Oncology
  • Urology

Background:

  • Localized prostate cancer (PCa) management is evolving rapidly.
  • Numerous clinical trials are underway, influencing treatment strategies.

Purpose of the Study:

  • To review recent phase III trial findings for localized PCa.
  • To update evidence-based management and discuss emerging innovations.
  • To synthesize current research for optimizing patient care.

Main Methods:

  • Review of recently completed phase III clinical trials.
  • Analysis of ongoing studies in localized prostate cancer.
  • Synthesis of evidence-based management approaches.

Main Results:

  • Advances in local therapy, lymph node management, and imaging are noted.
  • Systemic treatments and quality-of-life considerations are improving outcomes.
  • Emerging innovations show potential for enhanced patient care.

Conclusions:

  • Optimizing outcomes while minimizing toxicity is achievable with current advances.
  • Evidence-based approaches and new innovations are key to improving localized PCa care.
  • Continued research and clinical trials are vital for future progress.